Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial

Kuan Pin Su, Shih Yi Huang, Chih Chiang Chiu, Winston W. Shen

研究成果: 雜誌貢獻文章

406 引文 斯高帕斯(Scopus)

摘要

Patients with depression have been extensively reported to be associated with the abnormality of omega-3 polyunsaturated fatty acids (PUFAs), including significantly low eicosapentaenoic acid and docosahexaenoic acid in cell tissue contents (red blood cell membrane, plasma, etc.) and dietary intake. However, more evidence is needed to support its relation. In this study, we conducted an 8-week, double-blind, placebo-controlled trial, comparing omega-3 PUFAs (9.6 g/day) with placebo, on the top of the usual treatment, in 28 patients with major depressive disorder. Patients in the omega-3 PUFA group had a significantly decreased score on the 21-item Hamilton Rating Scale for Depression than those in the placebo group (P
原文英語
頁(從 - 到)267-271
頁數5
期刊European Neuropsychopharmacology
13
發行號4
DOIs
出版狀態已發佈 - 八月 2003

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

指紋 深入研究「Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial」主題。共同形成了獨特的指紋。

  • 引用此